Activist Starboard Value Takes $1 Billion Stake in Pfizer
Bloomberg Businessweek
Pfizer's Pandemic Aftermath: Challenges and Innovations
This chapter explores Pfizer's struggles post-COVID, including declining vaccine demand and investor dissatisfaction with acquisitions. It highlights the complexities of pharmaceutical innovation and the pressure on executives to maintain growth amid market fluctuations. Additionally, the discussion touches on the role of activist investors and the challenges faced in developing new medications.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
